Brokers Offer Predictions for Prime Medicine FY2025 Earnings

Prime Medicine, Inc. (NYSE:PRME) – Research analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Prime Medicine in a report released on Tuesday, December 23rd. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings per share of ($1.41) for the year. Lifesci Capital currently has a “Outperform” rating and a $6.00 target price on the stock. The consensus estimate for Prime Medicine’s current full-year earnings is ($1.68) per share. Lifesci Capital also issued estimates for Prime Medicine’s FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.78) EPS.

PRME has been the topic of several other research reports. Citigroup dropped their price objective on Prime Medicine from $5.00 to $4.25 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Prime Medicine in a research report on Monday, November 10th. Finally, Chardan Capital decreased their price objective on Prime Medicine from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.21.

Prime Medicine Trading Down 1.9%

Shares of PRME opened at $3.62 on Thursday. The stock has a market cap of $653.45 million, a P/E ratio of -1.77 and a beta of 2.70. Prime Medicine has a 1 year low of $1.11 and a 1 year high of $6.94. The stock’s 50-day moving average price is $4.16 and its two-hundred day moving average price is $4.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Prime Medicine by 1,316.4% during the third quarter. Russell Investments Group Ltd. now owns 6,827 shares of the company’s stock worth $38,000 after purchasing an additional 6,345 shares during the period. Jones Financial Companies Lllp bought a new position in Prime Medicine during the 3rd quarter worth $49,000. Sterling Investment Advisors Ltd. acquired a new position in Prime Medicine during the 3rd quarter worth about $55,000. Creative Planning bought a new stake in shares of Prime Medicine in the 2nd quarter valued at about $25,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of Prime Medicine in the third quarter valued at about $56,000. 70.37% of the stock is currently owned by institutional investors and hedge funds.

About Prime Medicine

Prime Medicine, Inc (NYSE: PRME) is a clinical-stage genetic medicines company focused on harnessing the potential of prime editing, an advanced CRISPR-derived gene editing technology. By refining the tools required for precise correction of disease-causing mutations, Prime Medicine aims to develop single-dose treatments that address underlying genetic drivers of disease. The company applies its proprietary engineering and delivery platforms to optimize on-target efficiency and minimize off-target effects, positioning itself at the forefront of next-generation gene editing therapeutics.

Prime Medicine’s research and development efforts span multiple therapeutic areas, including rare genetic disorders, immuno-oncology, and autoimmune diseases.